GlobeNewswire (Thu, 5:46PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
106 people get STML articles and Market Currents by email alert.
Get email alerts on STML »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
GlobeNewswire (Apr 25, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Feb 27, 2013)
-
GlobeNewswire (Feb 12, 2013)
-
GlobeNewswire (Feb 7, 2013)
-
-
-
-
5 IPOs Planned For This WeekRenaissance Capital IPO Research • Mon, Jan 28
-
-
-
6 IPOs Scheduled For The Week Of August 6IPOdesktop • Mon, Aug 6, 2012
-
6 U.S. IPOs Planned For The Week Of August 6Renaissance Capital IPO Research • Mon, Aug 6, 2012
-
-
-
4 IPOs Scheduled For The Week Of July 30IPOdesktop • Mon, Jul 30, 2012
To learn more about Seeking Alpha Pro, click here.
-
-
-
5 IPOs Planned For This WeekRenaissance Capital IPO Research • Mon, Jan 28
-
-
-
6 IPOs Scheduled For The Week Of August 6IPOdesktop • Mon, Aug 6, 2012
-
6 U.S. IPOs Planned For The Week Of August 6Renaissance Capital IPO Research • Mon, Aug 6, 2012
-
-
4 IPOs Scheduled For The Week Of July 30IPOdesktop • Mon, Jul 30, 2012
-
4 U.S. IPOs Planned For The Week Of July 30Renaissance Capital IPO Research • Mon, Jul 30, 2012
There are no Transcripts on STML.
-
GlobeNewswire (Thu, 5:46PM)
-
GlobeNewswire (Apr 25, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Feb 27, 2013)
-
GlobeNewswire (Feb 12, 2013)
-
GlobeNewswire (Feb 7, 2013)
STML vs. ETF Alternatives
Company Description
We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk. We believe that we are developing the most clinically advanced pipeline of anti-CSC... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 17, 10:08 AM Stemline Therapeutics (STML +6.2%) ramps higher after it prices its 4.2M share public offering at $14.50 per share, just a 3.3% discount to yesterday's close. The pricing puts the tally on gross proceeds at around $60M. The company intends to use the proceeds to fund ongoing clinical trials of its potential leukemia and lymphoma treatments SL-401 and SL-701, as well as for other general corporate purposes. Comment! [Healthcare, On the Move]
There are no StockTalks on this stock yet.